Drug Information

Drug General Information
Drug ID
D09JSM
Former ID
DNCL002198
Drug Name
IMC-3C5
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [523345]
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 3 Target Info Modulator [544262]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
NetPath Pathway TNFalpha Signaling Pathway
Pathway Interaction Database VEGF and VEGFR signaling network
VEGFR3 signaling in lymphatic endothelium
Reactome VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Signaling by VEGF
References
Ref 523345ClinicalTrials.gov (NCT01288989) A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 544262Bevacizumab and breast cancer: what does the future hold?. Future Oncol. 2012 April; 8(4): 403-414.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.